vimarsana.com
Home
Live Updates
Resverlogix Publishes on Apabetalones Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy : vimarsana.com
Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
Resverlogix Corp. today announced the publication of a peer-reviewed article, entitled Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human...
Related Keywords
Canada ,
United States ,
Toronto ,
Ontario ,
Canadian ,
Donald Mccaffrey ,
Ewelina Kulikowski ,
Alberta Newsfile Corp ,
Us Food Drug Administration ,
Resverlogix Corp ,
Twitter ,
Toronto Stock Exchange ,
Linkedin ,
Gene Expression ,
Primary Human ,
Highlights Include ,
Chief Scientific Officer ,
Breakthrough Therapy Designation ,
Drug Administration ,
Looking Statements ,
Annual Information Form ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.